GRAL — GRAIL, Inc.

Summary of GRAIL Q4 2025 Earnings Call

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $43.6 million, a 14% increase from Q4 2024, driven by $42.3 million in screening revenue (up 34% YoY).
• Full Year 2025 Revenue: $147.2 million, a 17% increase from 2024, with screening revenue at $138.6 million (up 28% YoY).
• Galleri Test Volume: Over 185,000 tests sold in 2025, with a 36% increase in volume.
• Net Loss: $99.2 million for Q4 2025 (up 2% YoY); full-year net loss of $408.4 million, an 80% improvement from 2024.
• Adjusted EBITDA: Negative $71.8 million for Q4 2025, an improvement of 15% YoY; full-year adjusted EBITDA negative $320.6 million, a 34% improvement YoY.
• Cash Position: $904.4 million at year-end, bolstered by equity placements.

2. Strategic Updates and Business Highlights:

• NHS-Galleri Trial Results: Significant reduction in Stage IV cancer diagnoses and a fourfold increase in overall cancer detection rates, although the primary endpoint (statistically significant reduction in combined Stage III and IV cancers) was not met.
• Expansion Plans: GRAIL plans to expand its field sales and medical teams to enhance commercial momentum, leveraging positive trial results.
• PMA Submission: Completed submission to the FDA for Galleri, with a review period expected to last about 12 months.
• Medicare Coverage Act: New federal law establishes a pathway for Medicare coverage of FDA-approved multi-cancer early detection tests.

3. Forward Guidance and Outlook:

• 2026 Sales Growth: GRAIL anticipates Galleri sales growth of 22% to 32% and aims for cash burn to not exceed $300 million.
• Long-Term Margin Target: Aiming for gross margins of 50% to 60% at scale, with progress noted in achieving these targets.

4. Bad News, Challenges, or Points of Concern:

• Trial Endpoint Miss: The NHS-Galleri trial did not meet its primary endpoint, raising concerns about the implications for FDA approval and Medicare coverage.
• Development Services Revenue Decline: A significant drop of 49% in development services revenue, indicating potential challenges in that segment.
• Increased Net Loss: Despite improvements, the net loss remains substantial, reflecting ongoing investment in growth and development.
• Market Sentiment: The stock reaction post-announcement indicated investor concerns regarding the trial results and their implications for future approvals.

5. Notable Q&A Insights:

• FDA Approval Probability: Management indicated that the probability of FDA approval remains unchanged despite missing the primary endpoint, emphasizing the focus on clinical performance and safety.
• Impact on Medicare Coverage: The company believes that the data from the NHS-Galleri trial will support their case for Medicare coverage, despite the primary endpoint miss.
• International Expansion Strategy: Management expressed confidence that the trial results would aid in discussions with other countries for Galleri's rollout.
• Future Follow-Up Plans: GRAIL plans to extend data collection from the NHS-Galleri trial by 6 to 12 months to gather more insights, which could potentially strengthen their case for clinical utility.

Overall, GRAIL's Q4 2025 earnings call highlighted a year of growth and strategic advancements, tempered by challenges related to trial outcomes and ongoing financial losses. The company remains optimistic about its future trajectory, particularly with anticipated FDA approval and Medicare coverage pathways.